Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06182631 · ClinicalTrials.gov registry record · Phase 3
Clinical Trial Testing Buzzy Bee vs Vapocoolant During IV Placement
A Phase 3 study of Intravenous Administration, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Phase 3
- Development phase
- 172
- Enrollment target
- 1
- Study location
NCT06182631: Completed Phase 3 study of Intravenous Administration, sponsored by State University of New York at Buffalo.
NCT06182631 is a Phase 3 study of Intravenous Administration that has completed, run by State University of New York at Buffalo. The registered enrollment target is 172 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06182631, a Phase 3 study of Intravenous Administration, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 172 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the anxiety and pain levels of patients when using Buzzy with ice, Vapocoolant, and placebo when inserting IV's line for IV fluids and/or phlebotomy in pediatric patients in the pediatric emergency department.
Primary Outcome
Wong- Baker Faces Pain Scale with scores: scale is 0-10, with 0 being no pain and 10 maximum pain. The changes in pain between the treatment groups were analyzed using chi square and one-way ANOVA for categorical and continuous variables respectively. Pre and post FACES pain scale-revised were reported as means and standard deviations
Conditions Studied
Interventions
- OTHER Placebo
- DEVICE Buzzy Bee
- DRUG Vapocoolent
Study Locations (1)
New York
- Oshei Childrens Hospital - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2021-01-15 |
| Phase | Phase 3 |
What the finished NCT06182631 record still lists
NCT06182631 is an interventional study that assigns participants to a tested intervention. The registered 172 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Intravenous Administration appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06182631 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06182631 about?
NCT06182631 is a clinical study titled "Clinical Trial Testing Buzzy Bee vs Vapocoolant During IV Placement". The purpose of this study is to compare the anxiety and pain levels of patients when using Buzzy with ice, Vapocoolant, and placebo when inserting IV's line for IV fluids and/or phlebotomy in pediatric patients in the pediatric emergency department.
What is the current status of trial NCT06182631?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 172 participants. The study started on 2019-07-15. Estimated completion is 2021-01-15.
What conditions does trial NCT06182631 study?
This clinical trial studies the following conditions: Intravenous Administration.
What interventions are being tested in trial NCT06182631?
The interventions under investigation include: Placebo (OTHER), Buzzy Bee (DEVICE), Vapocoolent (DRUG).
Who is sponsoring clinical trial NCT06182631?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06182631 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06182631's enrollment target sits among peer trials
172 1448th of 2000 higher than 550 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801797 · 172 participants · Phase 2
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
- NCT04867317 · 172 participants · Phase 3
Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)
- NCT05357040 · 172 participants · Phase 2
Antidepressant Effects of Nitrous Oxide
- NCT05587517 · 172 participants · Phase 2
A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI